Your browser doesn't support javascript.
Reduced antibody cross-reactivity following infection with B.1.1.7 than with parental SARS-CoV-2 strains.
Faulkner, Nikhil; Ng, Kevin W; Wu, Mary Y; Harvey, Ruth; Margaritis, Marios; Paraskevopoulou, Stavroula; Houlihan, Catherine; Hussain, Saira; Greco, Maria; Bolland, William; Warchal, Scott; Heaney, Judith; Rickman, Hannah; Spyer, Moria; Frampton, Daniel; Byott, Matthew; de Oliveira, Tulio; Sigal, Alex; Kjaer, Svend; Swanton, Charles; Gandhi, Sonia; Beale, Rupert; Gamblin, Steve J; McCauley, John W; Daniels, Rodney Stuart; Howell, Michael; Bauer, David; Nastouli, Eleni; Kassiotis, George.
  • Faulkner N; Retroviral Immunology, London, United Kingdom.
  • Ng KW; National Heart and Lung Institute, Imperial College London, London, United Kingdom.
  • Wu MY; Retroviral Immunology, London, United Kingdom.
  • Harvey R; High Throughput Screening STP, London, United Kingdom.
  • Margaritis M; Worldwide Influenza Centre, London, United Kingdom.
  • Paraskevopoulou S; Advanced Pathogen Diagnostics Unit UCLH NHS Trust, London, United Kingdom.
  • Houlihan C; Advanced Pathogen Diagnostics Unit UCLH NHS Trust, London, United Kingdom.
  • Hussain S; Advanced Pathogen Diagnostics Unit UCLH NHS Trust, London, United Kingdom.
  • Greco M; Division of Infection and Immunity, London, United Kingdom.
  • Bolland W; Worldwide Influenza Centre, London, United Kingdom.
  • Warchal S; RNA Virus Replication Laboratory, London, United Kingdom.
  • Heaney J; RNA Virus Replication Laboratory, London, United Kingdom.
  • Rickman H; Retroviral Immunology, London, United Kingdom.
  • Spyer M; High Throughput Screening STP, London, United Kingdom.
  • Frampton D; Advanced Pathogen Diagnostics Unit UCLH NHS Trust, London, United Kingdom.
  • Byott M; Advanced Pathogen Diagnostics Unit UCLH NHS Trust, London, United Kingdom.
  • de Oliveira T; Advanced Pathogen Diagnostics Unit UCLH NHS Trust, London, United Kingdom.
  • Sigal A; Department of Population, Policy and Practice, London, United Kingdom.
  • Kjaer S; Division of Infection and Immunity, London, United Kingdom.
  • Swanton C; Advanced Pathogen Diagnostics Unit UCLH NHS Trust, London, United Kingdom.
  • Gandhi S; School of Laboratory Medicine and Medical Sciences, University of KwaZulu-Natal, Durban, South Africa.
  • Beale R; KwaZulu-Natal Research Innovation and Sequencing Platform, Durban, South Africa.
  • Gamblin SJ; Centre for the AIDS Programme of Research in South Africa, Durban, South Africa.
  • McCauley JW; Department of Global Health, University of Washington, Seattle, United States.
  • Daniels RS; School of Laboratory Medicine and Medical Sciences, University of KwaZulu-Natal, Durban, South Africa.
  • Howell M; Africa Health Research Institute, Durban, South Africa.
  • Bauer D; Max Planck Institute for Infection Biology, Berlin, Germany.
  • Nastouli E; Structural Biology STP, London, United Kingdom.
  • Kassiotis G; Cancer Evolution and Genome Instability Laboratory, London, United Kingdom.
Elife ; 102021 07 29.
Article in English | MEDLINE | ID: covidwho-1332333
Preprint
This scientific journal article is probably based on a previously available preprint. It has been identified through a machine matching algorithm, human confirmation is still pending.
See preprint
ABSTRACT

Background:

The degree of heterotypic immunity induced by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) strains is a major determinant of the spread of emerging variants and the success of vaccination campaigns, but remains incompletely understood.

Methods:

We examined the immunogenicity of SARS-CoV-2 variant B.1.1.7 (Alpha) that arose in the United Kingdom and spread globally. We determined titres of spike glycoprotein-binding antibodies and authentic virus neutralising antibodies induced by B.1.1.7 infection to infer homotypic and heterotypic immunity.

Results:

Antibodies elicited by B.1.1.7 infection exhibited significantly reduced recognition and neutralisation of parental strains or of the South Africa variant B.1.351 (Beta) than of the infecting variant. The drop in cross-reactivity was significantly more pronounced following B.1.1.7 than parental strain infection.

Conclusions:

The results indicate that heterotypic immunity induced by SARS-CoV-2 variants is asymmetric.

Funding:

This work was supported by the Francis Crick Institute and the Max Planck Institute for Dynamics of Complex Technical Systems, Magdeburg.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 / Antibodies, Viral Type of study: Observational study / Randomized controlled trials Topics: Vaccines / Variants Limits: Humans Country/Region as subject: Africa / Europa Language: English Year: 2021 Document Type: Article Affiliation country: ELife.69317

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 / Antibodies, Viral Type of study: Observational study / Randomized controlled trials Topics: Vaccines / Variants Limits: Humans Country/Region as subject: Africa / Europa Language: English Year: 2021 Document Type: Article Affiliation country: ELife.69317